TherapeuticsMD reports positive Phase III results for vaginal atrophy drug, shares surge

Shares in women’s healthcare company, TherapeuticsMD (NYSEMKT: TXMD) jumped to close up nearly 39% Tuesday after the company said its drug candidate to treat moderate-to-severe dyspareunia or vaginal pain  met the main goals in late-stage trials.

The therapy is an applicator-free vaginal estradiol softgel.

TherapeuticsMD chief executive, Robert Finizio, said: “We look forward to sharing the Rejoice Trial results and to submitting a New Drug Application for TX-004HR to the Food and Drug Administration as soon as the first half of 2016.”